AIM ImmunoTech
Business Services · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2117 SW Highway 484, Ocala, Florida, 344...Phone Number
(352) 448-7797Website
www.aimimmuno.comRevenue
<$5 MillionStock Symbol
AIMIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
1
1
1
1
1
About AIM ImmunoTech
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Companys lead product, Ampligen® (rintatolimod), is an immuno-modulator with broad spectrum activity being developed for globally important cancers, viral diseases and disorders of the immune system.Explore more
AIM ImmunoTech Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AIM ImmunoTech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if AIM ImmunoTech had a recent Job posting/layoffs
Product Launch: Get notified when AIM ImmunoTech launches new products
Congratulate Masked Content for being promoted to Masked Content at AIM ImmunoTech
Check if AIM ImmunoTech has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once AIM ImmunoTech has new funding data
Website visits: Recent activity has been detected on your website
Check out if AIM ImmunoTech is spiking on competitors!
Earning: See what the market has to say on AIM ImmunoTech recently announced quarterly report
AIM ImmunoTech, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to AIM ImmunoTech
Compare insights from companies similar to AIM ImmunoTech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
AIM ImmunoTech is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
AIM ImmunoTech is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about AIM ImmunoTech.
AIM ImmunoTech Tech Stack
A closer look at the technologies used by AIM ImmunoTech
See more technologies
Most Recent Scoops
Project
AIM ImmunoTech has identified two key biomarker stratifications in its pancreatic cancer program a neutrophil-lymphocyte ratio of less than 4.5, associated with a median overall survival improvement of 22 months, and a CA 19-9 tumor marker threshold, associated with an overall survival improvement of 11.6 months highlighting the potential of Ampligen for a significant segment of the patient population.
Medical Research
Partnership
AIM ImmunoTech has entered into a collaboration agreement with AstraZeneca and Erasmus University Medical Center to conduct the DURAPANC Phase II trial, combining Ampligen with AstraZeneca's PD-L1 checkpoint inhibitor durvalumab for the treatment of metastatic pancreatic cancer.
Partnership
Project
AIM ImmunoTech has secured a U.S. patent for Ampligen in combination with PD-L1 checkpoint inhibitors for the treatment of cancers, including pancreatic cancer, and has been granted orphan drug designations in both the European Union and the United States, providing extended market exclusivity in those regions.
Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals
Project
AIM ImmunoTech has completed the MB-107 clinical trial of Anti-micin to treat soft tissue sarcoma lung metastases, delivering an overall survival of 13.5 months in very late-stage patients receiving an average of seventh-line treatment.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Medical Research, Pharmaceuticals, Clinical Operations
AIM ImmunoTech News & Media
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article
Article by CEO Thomas K. Equels calls for proactive evaluation of broad-spectrum antiviral countermeasures before novel viral threats emergeAIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer
Completed Enrollment and Ampligen Dosing in Metastatic Pancreatic Cancer Phase 2 Trial, Positioning Company for Key Clinical Milestones Through Early 2027AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point
Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027 Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding AIM ImmunoTech
Sign Up For FreeTo access detailed company insights
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Companys lead product, Ampligen® (rintatolimod), is an immuno-modulator with broad spectrum activity being developed for globally important cancers,... Read More
